Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Felici

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?Paolo Carlini, Paola Papaldo, Alessandra Fabi, et al.
Cancer|December 13, 2006
Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in OncologyLuca Moscetti, Fabrizio Nelli, Alessandra Felici, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinomaRoberto Iacovelli, Daniele Santini, Mimma Rizzo, et al.
Anti-Cancer Drugs|October 21, 2016
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetateSilvana Giacinti, Paolo Carlini, Michela Roberto, et al.
Breast (Edinburgh, Scotland)|May 3, 2008
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Giulio Metro, Gianluigi Ferretti, et al.
Clinical Genitourinary Cancer|May 11, 2019
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS TrialSergio Bracarda, Aristotelis Bamias, Jochen Casper, et al.
Clinical Pharmacokinetics|March 11, 2009
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic functionAlessandra Felici, Susanna Di Segni, Michele Milella, et al.
Expert Review of Anticancer Therapy|June 19, 2013
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectivesMatteo Santoni, Michele De Tursi, Alessandra Felici, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.
Journal of Neuro-Oncology|November 8, 2007
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding studyAlessandra Fabi, Alessandra Mirri, Alessandra Felici, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?Paolo Carlini, Paola Papaldo, Alessandra Fabi, et al.
Cancer|December 13, 2006
Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in OncologyLuca Moscetti, Fabrizio Nelli, Alessandra Felici, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinomaRoberto Iacovelli, Daniele Santini, Mimma Rizzo, et al.
Anti-Cancer Drugs|October 21, 2016
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetateSilvana Giacinti, Paolo Carlini, Michela Roberto, et al.
Breast (Edinburgh, Scotland)|May 3, 2008
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Giulio Metro, Gianluigi Ferretti, et al.
Clinical Genitourinary Cancer|May 11, 2019
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS TrialSergio Bracarda, Aristotelis Bamias, Jochen Casper, et al.
Clinical Pharmacokinetics|March 11, 2009
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic functionAlessandra Felici, Susanna Di Segni, Michele Milella, et al.
Expert Review of Anticancer Therapy|June 19, 2013
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectivesMatteo Santoni, Michele De Tursi, Alessandra Felici, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.
Journal of Neuro-Oncology|November 8, 2007
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding studyAlessandra Fabi, Alessandra Mirri, Alessandra Felici, et al.
Pageof 6